

BD CTGCTV2 / BD CTGC2 for BD MAX™ System

Real-time PCR assays

The need for co-testing *Chlamydia trachomatis*, *Neisseria gonorrhoeae* and *Trichomonas vaginalis*

Global sexually-transmitted infection (STI) surveillance data from 2016 released by the World Health Organization (WHO) estimated that there are **376 million new cases per year of four common non-viral STIs:** *Chlamydia trachomatis* (CT), *Neisseria gonorrhoeae* (GC), *Trichomonas vaginalis* (TV) and syphilis.[1]

CT and GC are the two most reported bacterial STIs in Europe.[2] Although **TV** remains a non-notifiable disease, it is one of the most prevalent STI in the world and **likely causes more STIs than CT and GC combined in many populations**.[2,3] Screening populations at risk of CT, GC and TV infection contributes to overall disease reduction and reduces adverse health outcomes due to STIs.[2,4] To encourage routine screening, it is critical for labs and healthcare systems to offer STI tests that have a quick time-to-result and user-friendly techniques for processing.[5]

Discover the assay

The **BD CTGCTV2 for the BD MAX™ System** is an automated assay including nucleic acid real-time polymerase chain reaction (PCR) for direct and qualitative detection and differentiation of DNA targets from: • *Chlamydia trachomatis (2 targets)* • *Neisseria gonorrhoeae (2 separated targets)* • *Trichomonas vaginalis*

With BD CTGC2 for the BD MAX™ System also available, you have the **flexibility to test either for CT and GC or CT,GC and TV from a single specimen collection based on patient risk, for both symptomatic and asymptomatic men and women.**

These tests also include a sample processing control.

Sample types

- Vaginal swab (clinician or patient collected)
- Endocervical swab (clinician collected)
- Urine for male and women
- PreservCyt Liquid Based Cytology (LBC) Media

Workflow and time to results

Results obtained in just above **2.5 hours for 24 samples**

Less than **1.5 minutes of hands-on time** in sample preparation

Compatibility to run alongside other BD MAX™ assays on 1 to 24 specimens simultaneously for greater flexibility

Scientific evaluation

Read more about the **BD CTGCTV2 for BD MAX™ System** from molecular studies and publications.

Van der Pol et al., Clinical Performance of the BD CTGCTV2 Assay for the BD MAX™ System for Detection of Chlamydia trachomatis, Neisseria gonorrhoeae, and Trichomonas vaginalis Infections, Sex Transm Dis. 2021 Feb 1;48(2):134-140.

Ready-to-use reagents storable at room temperature

REF	Contents	Quantity
443906 (BD CTGTV2 for BD MAX™ System) or 443905 (BD CTGC2 for BD MAX™ System)	**BD CTGCTV2 or BD CTGC2 for BD MAX™ System Master Mix** Dried PCR Master Mix containing nucleotides and specific molecular primers and probes along with Sample Processing Control and PCR enzyme	24 tests (2 x 12 tubes)
	BD CTGCTV2 or BD CTGC2 for BD MAX™ System Unitised reagent strip containing wash buffer, elution buffer, and neutralisation buffer reagents, as well as disposable pipette tips necessary for sample processing and DNA extraction	24 strips
	BD CTGCTV2 or BD CTGC2 for BD MAX™ System Extraction Tubes (B2) Dried extraction reagent containing DNA magnetic affinity beads, protease reagents and Sample Processing Control	24 tests (2 x 12 tubes)

Rapid, targeted testing on the BD MAX™ System

The innovation of the BD MAX™ System offers you a **fully integrated, automated real-time PCR platform** with the possibility of running multiple assays simultaneously.* Its automated workflow **reduces manual tasks** to achieve rapid, reliable results and facilitates off-hour testing, helping to **offset molecular testing costs**.** [6,7]

Snap

Assemble unitised reagent strips with ready-to-use reagents.

Load

Load Sample Buffer Tubes, Racks and PCR cartridges.

Go

Come back in an average of 2.5 hours for results.***

Discover our full assay portfolio and the BD MAX™ System

advancing-diagnostics.eu advancingdiagnostics@bd.com

BD CTGCTV2 for BD MAX™ System [IFU 443906]. Franklin Lakes, NJ: Becton, Dickinson, and Company; 2021.
BD CTGC2 for BD MAX™ System [IFU 443905]. Franklin Lakes, NJ: Becton, Dickinson, and Company; 2021.

1. World Health Organization (WHO). *Report on global sexually transmitted infection surveillance 2018*. Accessed January 2022, at https://www.who.int/reproductivehealth/publications/stis-surveillance-2018/en/ **2.** European Centre for Disease Prevention and Control (ECDC). *Developing a national strategy for the prevention and control of sexually transmitted infections*. Accessed January 2022, at https://www.ecdc.europa.eu/sites/default/files/documents/strategies-to-control-STIs.pdf **3.** Van Der Pol B, et al. Combined Testing for Chlamydia, Gonorrhea, and Trichomonas by Use of the BD Max CT/GC/TV Assay with Genitourinary Specimen Types. *Journal of Clinical Microbiology*. 2017;55(1):155–164. https://pubmed.ncbi.nlm.nih.gov/27795343/. **4.** Centers for Disease Control and Prevention (CDC). *Sexually Transmitted Infections: National Strategic Plan for the United States, 2021-2025*. Accessed January 2022, at https://www.hhs.gov/sites/default/files/STI-National-Strategic-Plan-2021-2025.pdf **5.** Van Der Pol B, et al. Clinical Performance of the BD CTGCTV2 Assay for the BD MAX™ System for Detection of *Chlamydia trachomatis*, *Neisseria gonorrhoeae*, and *Trichomonas vaginalis* Infections. *Sexually Transmitted Diseases*. 2021;48(2):134-140. doi: 10.1097/OLQ.0000000000001280. **6.** Mortensen JE, et al. Comparison of time-motion analysis of conventional stool culture and the BD MAX™ Enteric Bacterial Panel (EBP). *BMC Clin Pathol*. 2015;15:9. **7.** Hirvonen JJ, et al. Comparison of BD Max Cdiff and GenomEra C. *difficile* molecular assays for detection of toxigenic Clostridium difficile from stools in conventional sample containers and in FecalSwabs. *Eur J Clin Microbiol Infect Dis*. 2015;34(5):1005-1009.

* BD assays are run & rack compatible – Only MDR-TB and GBS are not run and rack compatible / Vaginal Panel and open systems' assays are only run compatible.
** When compared to culture or immunochromatographic antigen (IA).
*** Time is assay dependent. 4 hours for full results on MDR-TB assay.

The BD MAX™ System is an in-vitro diagnostic medical device bearing a CE-mark.
The BD CTGCTV2 & BD CTGC2 for BD MAX™ System are in-vitro diagnostic medical devices bearing a CE-mark, and are CE certified by BSI Group The Netherlands B.V. (Notified Body Number = 2797).

CE CE
2797